

## **ACORDA THERAPEUTICS INC**

# Reported by PHILLIPS BARCLAY A

### FORM 3

(Initial Statement of Beneficial Ownership)

## Filed 02/09/06 for the Period Ending 02/09/06

Address 420 SAW MILL RIVER ROAD

ARDSLEY, NY 10502

Telephone 914-347-4300

CIK 0001008848

Symbol ACOR

SIC Code 2836 - Biological Products, Except Diagnostic Substances

Industry Biotechnology & Drugs

Sector Healthcare

Fiscal Year 12/31





## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2008 Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *  PHILLIPS BARCLAY A	2. Date of Event Requiring Statement (MM/DD/YYYY) 2/9/2006			3. Issuer Name and Ticker or Trading Symbol  ACORDA THERAPEUTICS INC [ACOR]					
(Last) (First) (Middle)	4. Relatio	nship of Rep	porting Perso	g Person(s) to Issuer (Check all applicable)					
C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE	X Director Officer (give title below)		pw)	10% Owner Other (specify below)					
HAWTHORNE, NY 10532	5. If Amendment, Date Original Filed (MM/DD/YYYY)		_ <b>X</b> _ Fe	6. Individual or Joint/Group Filing (Check Applicable Line)  _X _ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)									
	Table I - N	Non-Deriva	tive Securitio	es Beneficially	Owned				
1.Title of Security 2. A			ount of Securicially Owned	t of Securities ly Owned  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  4. Nature of Indirect Beneficial Ownership (Instr. 5)			rect Beneficial		
Table II - Derivative Secu	ırities Benef	icially Own	ed ( <i>e.g.</i> , pu	ts, calls, warr	ants, options	, convertible	e securities)		
1. Title of Derivate Security (Instr. 4)	2. Date Exer and Expirati	2. Date Exercisable and Expiration Date (MM/DD/YYYYY) 3. See De		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		5. Ownership Form of Derivative Security:	6. Nature of Indirect		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)			
Series E-1 Convertible Preferred Stock	(1)	(1)	Common Stock	53640 (2)	\$13.806	I	See Footnotes (3)		
Series E-1 Convertible Preferred Stock	(1)	(1)	Common Stock	17880 <sup>(2)</sup>	\$13.806	I	See Footnotes (4)		
Series E-2 Convertible Preferred Stock	(1)	(1)	Common Stock	163700 (2)	\$13.806	I	See Footnotes (3)		
Series E-2 Convertible Preferred Stock	(1)	(1)	Common Stock	54566 <sup>(2)</sup>	\$13.806	I	See Footnotes (4)		
Series H Convertible Preferred Stock	(1)	(1)	Common Stock	24453 (2)	\$15.3348	I	See Footnotes (3)		

Table II - Derivative Security  1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		ad ( e.g. , puts, calls, warra 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4.	5. Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Series H Convertible Preferred Stock	(1)	(1)	Common Stock	8150 (2)	\$15.3348	I	See Footnotes (4)	
Series I Convertible Preferred Stock	(1)	(1)	Common Stock	67945 <sup>(2)</sup>	\$17.1132	I	See Footnotes (3)	
Series I Convertible Preferred Stock	(1)	(1)	Common Stock	22647 (2)	\$17.1132	I	See Footnotes (4)	
Series J Convertible Preferred Stock	(1)	(1)	Common Stock	98116 <sup>(2)</sup>	\$7.644	I	See Footnotes (3)	
Series J Convertible Preferred Stock	(1)	(1)	Common Stock	32704 (2)	\$7.644	I	See Footnotes (4)	

#### **Explanation of Responses:**

- (1) The convertible preferred stock is convertible at any time, at the holder's discretion, and has no expiration date.
- (2) The number of shares underlying convertible preferred stock in column 3 of Table II represents the number of shares of Common Stock of the Issuer that the convertible preferred stock will automatically convert into upon the closing of the Issuer's initial public offering.
- (3) These shares are held by Vector Later-Stage Equity Fund II (QP), L.P. ("Vector QP"). According to information provided by Vector QP, Mr. Phillips could be deemed to have shared voting and dispositive power with respect to the shares of stock held by Vector QP. However, Mr. Phillips disclaims beneficial ownership except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed to be an admission that he is the beneficial owner of these securities for purposes of Section 16.
- (4) These shares are held by Vector Later-Stage Equity Fund II, L.P. ("Vector"). According to information provided by Vector, Mr. Phillips could be deemed to have shared voting and dispositive power with respect to the shares of stock held by Vector. However, Mr. Phillips disclaims beneficial ownership except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed to be an admission that he is the beneficial owner of these securities for purposes of Section 16.

#### Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

Reporting Owners

Reporting Owners					
Deporting Orymon Name / Address	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
PHILLIPS BARCLAY A C/O ACORDA THERAPEUTICS, INC.					
	X				
15 SKYLINE DRIVE					
HAWTHORNE, NY 10532					

#### **Signatures**

/s/ Michelle Meyers, by power of attorney 2/9/2006

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### POWER OF ATTORNEY

#### For Executing Forms 3, 4 and 5

Know all by these presents, that the undersigned hereby constitutes and appoints each of Ron Cohen, Jane Wasman, David Lawrence and Michelle Meyers, or any of them acting singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID, including any amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- 2. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC, Forms 3, 4 and 5, and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and file such form with the SEC and any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his/her discretion.

The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his/her substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Acorda Therapeutics, Inc. assuming, any of the undersigned's responsibilities to comply with Section 16(a) of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Acorda Therapeutics, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

/s/ Barclay A. Phillips Signature
Barclay A. Phillips Print Name

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6 <sup>th</sup> day of February, 2006.